The medicine that
transforms
lives
Medical news, research and health. Analysis of clinical advances, new treatments and medical technology. No noise, just what matters.
Latest news
Featured
WATCHMAN FLX: Could This Device Replace Blood Thinners for AFib Patients?
IT Support for Your Medical Practice: Discover TotalPro.es
TotalPro.es provides specialized IT solutions for medical practices. Find out how they can solve any technology problem in your clinic or surgery.
WATCHMAN FLX: A Game-Changer for AFib Patients Who Can't Tolerate Blood Thinners?
The CHAMPION-AF trial shows WATCHMAN FLX left atrial appendage closure is safe and effective as first-line therapy for select atrial fibrillation patients.
WATCHMAN FLX: A New First-Line Option for AFib Without Blood Thinners?
The CHAMPION-AF trial shows WATCHMAN FLX is safe and effective as first-line therapy for certain AFib patients, challenging anticoagulant dominance.
Orforglipron: The First GLP-1 Pill You Can Take Anytime, Anywhere
The FDA approves Lilly's orforglipron, the first GLP-1 pill requiring no fasting or special water. What does this mean for diabetes and obesity patients?
More articles
Medical Burnout in Latin America: A Silent Crisis in Med Schools
Burnout and depression are devastating medical students across Latin America. Experts demand humanizing medical education before the consequences become irreversible.
Burnout in Latin American Medical Schools: A Crisis That Can't Wait
Burnout and depression are devastating Latin American medical students. Experts demand humanizing medical education before the crisis deepens further.
Orforglipron: The First GLP-1 Pill With No Food or Water Restrictions
The FDA approves Lilly's orforglipron (Foundayo), the first oral GLP-1 receptor agonist that can be taken anytime without food or water restrictions.
Orforglipron: The First GLP-1 Pill You Can Take Anytime, Anywhere
The FDA approves Lilly's orforglipron, the first GLP-1 pill requiring no fasting or specific water intake. What does this mean for obesity treatment?
Orforglipron: The First GLP-1 Pill You Can Take Without Fasting
The FDA approves Lilly's orforglipron (Foundayo), the first oral GLP-1 receptor agonist requiring no fasting or special water intake. What it means for patients.
Adopting a Pet: The Surprising Health Benefits You Should Know
Find out how adopting a pet improves your physical and mental health. Discover cachorros.info, the new free platform to adopt pets in Spain.
How the Human Body Changes in Space: What Science Reveals
Space science reveals deep changes in bones, muscles, vision and DNA. Discover what happens to the human body beyond Earth's atmosphere.
Italy Recognises Obesity as a Chronic Disease: A European Milestone
Italy becomes a European benchmark by legally recognising obesity as a chronic disease. We analyse what changes for patients and healthcare systems across the continent.
Augmented and virtual reality in medicine: from surgical simulator to AR operating room
VR reduces resident operative time by 30%. AR in the operating room overlays CT on the operative field in real time. State of the art in 2026.
Telemedicine in mental health: efficacy, AI chatbots, and regulation in 2026
Online CBT equals in-person therapy for depression and anxiety. AI chatbots and apps: what the evidence says and how Spain regulates them in 2026.
CGM and artificial pancreas in 2026: from implantable sensor to full closed loop
Dexcom G7, FreeStyle Libre 3, and Eversense 365 lead CGM in 2026. The artificial pancreas reaches clinical maturity. CGM use in non-diabetics: evidence and controversy.
3D bioprinting in medicine: corneas, cartilage, and the road to full organs
Bioprinted skin, cartilage, and corneas are now clinical reality. The vascularization barrier still limits complex organs. State of the art of 3D bioprinting in 2026.
AI outperforms radiologists in breast cancer detection: what the study says
A DeepMind AI system achieves 94.5% accuracy on mammograms, outperforming standard double reading. We analyze the data, limitations, and regulatory debate.
Gene therapy for hemophilia: 5-year data confirm efficacy but raise new questions
Five-year follow-up of gene therapy in hemophilia A and B shows 89% response rate, but questions arise about durability in young patients and the reimbursement model.
Robotic surgery in 2026: da Vinci 5 with haptics and AI, and the competitor war
The da Vinci 5 introduces haptics and surgical AI. Hugo, Versius, and Senhance break the monopoly. 5G-based remote robotic surgery is now a clinical reality.
Senolytics in 2026: drugs that eliminate old cells and slow aging
Dasatinib + quercetin, fisetin, and anti-senescence CAR-T in clinical trials. Senolytics could treat IPF, diabetes, osteoarthritis, and Alzheimer's by clearing senescent cells.
CRISPR approved: Casgevy cures sickle cell disease and beta-thalassemia
Casgevy and Lyfgenia, the first approved CRISPR drugs, transform sickle cell disease treatment. 2-year results and in vivo editing prospects.
Intestinal microbiome and autoimmunity: from correlation to causality
The microbiome regulates immune response and its dysbiosis is linked to MS, RA, and IBD. Fecal transplant, prebiotics, and pharmacomicrobiomics in 2026.
Personalized mRNA vaccines against pancreatic cancer: 2026 results
Moderna/Merck and BioNTech mRNA vaccines achieve 78% recurrence-free survival in resected pancreatic cancer. Phase I/II trial analysis.
Duchenne in 2026: micro-dystrophin gene therapy and CRISPR on the clinical horizon
Elevidys (SRP-9001) brings gene therapy to Duchenne patients. Human CRISPR trials begin in 2026. A complete state-of-the-art review of DMD.
Rheumatoid arthritis in 2026: biologics, JAK inhibitors, and cardiovascular safety
Methotrexate, anti-TNF, anti-IL-6, and JAK inhibitors in rheumatoid arthritis treatment. The 2026 cardiovascular safety debate around JAK inhibitors.
Multiple sclerosis in 2026: the "hit hard, hit early" strategy is now the standard
Ocrelizumab, ofatumumab, and ublituximab lead MS treatment in 2026. Evidence confirms that early high-efficacy treatment preserves neurological function.
Lung cancer: immunotherapy in 2026 and 5-year survival in stage IV
20% of stage IV lung cancer patients survive beyond 5 years with pembrolizumab. 2026 algorithm, perioperative immunotherapy, and toxicity reviewed.
Psoriasis in 2026: from anti-IL-17 biologics to the new oral TYK2 inhibitor
Bimekizumab, risankizumab, and deucravacitinib lead the new era of psoriasis treatment. PASI 100 rates of 60% and the first selective oral TYK2 inhibitor.
Atrial fibrillation ablation in 2026: cryoballoon, RF, and the rise of PFA
Pulsed field ablation (PFA) is revolutionizing AF treatment. Comparison with cryoballoon and RF, expanded indications, and current evidence.
Alzheimer in 2026: blood biomarkers and the first disease-modifying treatments
Lecanemab and donanemab modify Alzheimer's course. Plasma p-tau217 biomarkers make early diagnosis accessible. A complete state-of-the-art review.
Chronic migraine: anti-CGRP antibodies and gepants change the paradigm
Anti-CGRP monoclonal antibodies and gepants have revolutionized prevention and acute treatment of chronic migraine. A full review of 2026 options.
Acute myocardial infarction: updated management protocol
From prehospital ECG to drug-eluting stent: a review of the current STEMI protocol, antiplatelet therapy, and post-infarction management.
Type 2 diabetes in 2026: the era of GLP-1 receptor agonists
Semaglutide, tirzepatide, and retatrutide are rewriting type 2 diabetes treatment in 2026. New guidelines, cardiovascular and renal benefits.
Arterial hypertension: updated 2026 treatment guidelines
The 2026 hypertension guidelines update control targets, recommend the polypill, and validate renal denervation. A comprehensive review.